Skip to NavigationSkip to content

News

0
FDA knocks back Biohaven's ALS drug over manufacturing concerns
Biohaven Pharmaceutical has seen its new therapy formulation for the treatment of amyotrophic lateral sclerosis (ALS) rejected by the FDA, it has...
0
NICE to review its decision making processes
Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, and diagnostics.
0
Celgene's Otezla becomes first and only FDA-approved therapy for oral ulcers in Behçet’s Disease
Celgene has revealed the US approval of Otezla for the treatment of with oral ulcers in adult patients with the rare and chronic inflammatory...
0
Government spend £9.2 billion on private healthcare providers for NHS in 2018-19
The Department of Health and Social Care (DHSC) paid £9.2 billion to private providers in the year prior to 31 March 2019, according to their annual...
>> More News Stories

Features

Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world

The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the quality of generics has been sacrificed in the...

>> More Features
>> More News Stories